Infectious disease remains an important threat to mankind. Pathogens can cause severe illness, deformation, disability, or death, and might be responsible for certain kinds of cancer, neurological diseases and heart diseases, etc. Anti-bacterial drugs have been considered amongst the most paramount achievements of the 20th century in medicine, and indeed application of antibiotics have made significant contribution to human health and medical practice. In the past decade, the success in treating pathogen infection has been extended from bacterial infection to viral diseases. Recent clinical results of new drugs against AIDS and hepatitis C have been very encouraging.
However, the success in drug R&D against infectious diseases has been accompanied with the emergence of drug-resistant strains as well as newly emerging infectious pathogens. It represents an endless war between humans and pathological microbes, and is considered a grand challenge in global health. To meet the need, biologists in the field of drug discovery for infectious diseases show more interest on acquiring new targets on pathogens; some of them start their research on innate immunity as well as host molecules required for pathogen replication. New compounds with novel backbone structures and anti-pathogenic activity are subjects of interest for medicinal chemists. The goal is to discover drugs that act via new mechanisms against pathogens, especially drugresistant pathogens and newly emerging infectious agents. This special issue collects reviews and research articles from groups that have a long history of doing research on drugs against infectious diseases. I hope the forum to be informative for our readers.
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Chronic hepatitis B virus (HBV) infection affects more than 350 million people worldwide and remains to be one of the most important public health challenges. While currently available antiviral therapies can efficiently reduce HBV load as well as prevent liver disease progression, cure or durable off-drug control of HBV infection are rarely achieved. Encouraged by the recent milestone of therapeutic cure of chronic hepatitis C virus infection, significant academic and industrial efforts are now focusing on finding a cure for chronic hepatitis B. The review article by Chang and colleagues thoroughly analyzes the major obstacles for the functional cure of chronic HBV infection. Therapeutic strategies to overcome these obstacles are proposed.
